Article Information
History
- April 17, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Miriam Ferreiro-Pantín1,2,
- Urbano Anido-Herranz1,3,*,
- Yoel Z. Betancor1,2,*,
- Víctor Cebey-López1,3,
- Luis León-Mateos1,3,4,
- Jorge García-González1,3,4,
- Silvia Margarita García-Acuña5,
- Natalia Fernández-Díaz1,3,
- Jose M. C. Tubio2,
- Rafael López-López1,3,4,6 and
- Juan Ruiz-Bañobre1,2,3,4,6,#
- 1Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
- 2Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
- 3Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela (SERGAS), University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
- 4Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029 Madrid, Spain
- 5Department of Pathology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706 Santiago de Compostela, Spain
- ↵#Corresponding author: Dr. Juan Ruiz-Bañobre; Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, Travesía da Choupana S/N, 15706 Santiago de Compostela, Spain. Phone: (034)981951470., Email: juan.ruiz.banobre{at}sergas.es
↵* These authors contributed equally to this work.
Posted April 17, 2023.
Clinical, molecular, and immune correlates of Immunotherapy Response Score in advanced urothelial carcinoma patients under atezolizumab monotherapy: Analysis of the phase 2 IMvigor210 trial
